At EBMT25, Dr. Janaki Manoja Vinnakota presented compelling data on the role of microglial TAK1 activation in the development of CAR T cell therapy-associated neurotoxicity (ICANS). In her presentation titled “Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome”, she demonstrated how TSPO-PET imaging and preclinical models were used to map myeloid activation and cognitive dysfunction linked to ICANS.
The study showed that selective TAK1 inhibition in microglia significantly mitigated neurotoxicity while preserving anti-tumor response. This opens the door to potential therapeutic strategies that enhance the safety of CAR T cell therapy.
Congratulations to Dr. Vinnakota and her team for this impactful contribution to the field of cellular immunotherapy.
For more details, visit: https://lnkd.in/dzCKPt-z
